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Thalassaemia and hereditary spherocytosis (HS) are the
most common inherited haemolytic anaemias, in general.
However, a-thalassaemia is found mostly in patients of
Mediterranean or South-East Asian origin and results




Subjects with three functional a-globin genes ()a⁄aa) are
clinically and haematologically silent and those with
two functional a-globin genes ()a⁄)a or –⁄aa, termed
a-thalassaemia trait) present only very mild hypochromic
microcytic anaemia (1).
In contrast, hereditary spherocytosis occurs in all
racial groups and is particularly common in Northern
European countries, with a prevalence of approximately
1 in 2000 (2).
The primary defects in HS reside in the erythrocyte
membrane proteins that are involved in the interac-
tions between the membrane skeleton and the lipid
bilayer: spectrin, ankyrin, band 3 and protein 4.2 (3).
Isolated deﬁciency of protein 4.2 is a very common
cause of HS in Japan (about 50% cases) but is rare in
other populations, accounting for about 5% of all HS
cases (4, 5). The only ﬁve protein 4.2 defects reported
outside the Japanese population are: protein 4.2 Tozeur,
Lisboa, Nippon, Nancy and Hammersmith, found in
patients of Tunisian, Portuguese, Italian, French and
South Asian origin respectively (6–10).
Here, we report the 3.7-kb a-thalassaemia-causing
deletion, )a
3.7⁄)a
3.7 in a Polish patient who was also
found to bear two novel protein 4.2 gene mutations dis-
covered in the form of compound heterozygosity.
Patient and methods
Case report
Informed consent was obtained from the patient’s
parent. The study protocol was approved by the Ethics
Committee of the Medical University of Warsaw.
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outpatient department of haematology since birth
because of haemolytic anaemia of unknown aetiology.
The girl was initially treated with ferrum supplements,
but without effect. She had never undergone transfusion
and had never been treated with hematopoietic drugs.
The RBC parameters did not clearly indicate the cause
of the anaemia (Table 1). Eosin-5-maleimide (EMA)
labelling of red blood cells and ﬂow cytometry were per-
formed as a screening test for HS and did not reveal a
decrease in ﬂuorescence intensity. Sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE)
results did not shown prominent changes in erythrocyte
membrane protein levels. Therefore, a diagnosis of hered-
itary spherocytosis was initially excluded. Enzymopathy
of red cells (glucose-6-phosphate dehydrogenase – 18.3,
hexokinase – 1.3, glucose phosphate isomerase – 36.7,
pyruvate kinase – 14.3 jm/gHb) and autoimmunohaemo-
lytic anaemia were also excluded.
The blood smear showed microcythosis (Fig. 1). The
bilirubin level ranged from 1.5 to 1.8 mg⁄dL (max).
Additional studies revealed a ferritin level between 70
and 180 ng⁄mL, lactate dehydrogenase 448–662 U⁄L and
Fe 47.0–105 lg⁄dL. Abdominal ultrasonography exami-
nation showed splenomegaly (138 mm).
Blood studies of the patient’s mother (conducted out-
side of outpatient clinic) suggested a thalassaemic trait:
decreased levels of mean corpuscular volume (MCV –
69.7 fL), mean corpuscular haemoglobin (MCH –
21.9 pg), and an RBC count of 5.52 (10
6⁄lL). The
patient’s brother and sister were not anaemic and her
father was not available to the study.
Quantitation of erythrocyte membrane proteins
A ﬂow cytometric test with the use of eosin-5-maleimide,
a dye that covalently reacts with Lys430 of the band 3
protein (11), was performed to detect membrane-associ-
ated inherited haemolytic anaemia. Erythrocyte mem-
brane protein levels were measured by SDS-PAGE.
RNA isolation and reverse transcription
Total RNA was isolated from peripheral blood samples
using the PAXgene Blood RNA Kit (QIAGEN, Hilden,
Germany). Reverse transcription was performed using
QuantiTect Reverse Transcription Kit (QIAGEN)
according to the manufacturer’s recommendations.
mRNA relative quantiﬁcation
mRNA relative quantiﬁcation for the genes of erythrocyte
membrane proteins was carried out using real-time poly-
merase chain reaction (PCR). qPCR ampliﬁcation was
performed using LightCycler 1.5 and LightCycler Fast-
Start DNA Master SYBR Green I (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufac-
turer’s recommendations. The Pfafﬂ model (12) and the
Table 1 Haematological parameters of the proband
Age Sex RBC (10
6⁄lL) Ret (%) Ht (%) Hb (g⁄dL) MCV (fL) RDW (%) MCH (pg) MCHC (g⁄dL) HbA2 (%) HbF (%)
Normal value – F 4.2–5.4 0.6–2.6 37–47 12–16 81–99 11–15 27–31 32–36 >2.5 >1
Proband 16 F 4.67 6.6 28.7 8.7 61.4 24.1 18.7 30.4 2.0 1.1
Ret, reticulocytes; Ht, hematocrit; MCHC, mean corpuscular haemoglobin concentration; HbA2 , haemoglobin A2; HbF, haemoglobin F; MCV,
mean corpuscular volume; RDW, red cell distribution width; MCH, Mean corpuscular volume.
A
B
Figure 1 (A) May–Grunwald–Giemza staining of erythrocytes (micros-
pherocyte marked with arrow). (B) Reticulocytes staining performed
with brilliant cresyl blue.
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ª) (13) were
used to estimate the relative changes in mRNA levels of
ankyrin, spectrins, band 3 and protein 4.2 as well as globin
genes in the analysed patient (compared with 10 healthy
individuals). Data normalisation was carried out against
the transcript of the gene for EMP55 (erythrocyte mem-
brane protein p55).
DNA isolation
A DNA Isolation Kit for Blood⁄Bone Marrow⁄Tissue
(Roche Diagnostics GmbH) was used to isolate DNA
from blood samples.
Detection of the a-thalassaemia deletion )a
3.7 by mul-
tiplex PCR
The multiplex PCR method was utilised for detection of
the common a-thalassaemia deletion )a
3.7, as previously
described (14).
Detection of protein 4.2 gene mutations
PCR was used to amplify the entire coding sequence, pro-
moter region and surrounding sequences of the EPB42
gene. DNA fragments generated by PCR ampliﬁcation
were puriﬁed using QIAquick PCR Puriﬁcation Kit (QIA-
GEN) and directly sequenced. As the detected nucleotide
substitution creates a new restriction site, we performed
restriction analysis with the RsaI enzyme (Roche Diagnos-
tics GmbH) to conﬁrm the presence of the A567T muta-
tion. The IVS2nt+6T>A substitution was veriﬁed by
sequencing of a separate PCR product, obtained with a
separate set of primers, different from those used for the
initial sequencing. The absence of the identiﬁed genetic
changes was conﬁrmed among at least 50 healthy individ-
uals. The sequences of all primers and the annealing tem-
peratures used in this study are available upon request.
Results
Quantitation of erythrocyte membrane proteins
EMA labelling of red blood cells and ﬂow cytometry did
not reveal a decrease in ﬂuorescence intensity in the
proband (92.99% of control). The erythrocyte membrane
protein levels of the analysed patient were normal (data
not shown). Her family members were not available for
the molecular studies.
Globin genes mRNA relative quantiﬁcation and identi-
ﬁcation of the a-thalassaemia deletion )a
3.7
mRNA relative quantiﬁcation of the globin genes
revealed a decreased a-globin transcript level when com-
pared with the control group (Table 2). DNA analysis of
the a-globin gene showed the presence of the 3.7 kb dele-




Erythrocyte membrane protein genes mRNA relative
quantiﬁcation and the identiﬁcation of mutations in
the protein 4.2 gene
Relative mRNA quantiﬁcation was carried out for the
red blood cell membrane protein genes at the same time.
The patient displayed increased transcript levels of the
genes for ankyrin, band 3 and spectrin a, and an approx-
imately 45% decrease in the relative mRNA level of the
gene encoding the protein 4.2 (EPB42) in comparison
with the control group (Table 2). The next stage of our
studies involved sequencing of the protein 4.2 gene to
ﬁnd a cause of the decreased mRNA level. Direct
sequencing of the EPB42 gene revealed the presence of
two previously undescribed mutations in heterozygotic
form in the proband. The G1701A mutation is located in
exon 10 and predicts an alanine to threonine change at
position 567 (A567T). The presence of this substitution
at the DNA level was veriﬁed using RsaI restriction
enzyme analysis (Fig. 2A) and by sequencing at the
cDNA level. The second genetic change identiﬁed, the
T ﬁ A substitution, is located at position +6 of
the donor splice site of intron 2 (IVS2nt+6T>A). The
presence of this mutation was conﬁrmed by sequencing
(Fig. 2B).
Discussion
The case of the hereditary haemolytic anaemia described
here represents an atypical type of a-thalassaemia that
coexists with the erythrocyte membrane protein 4.2 gene
mutations. Protein 4.2 defects are known to cause heredi-
Table 2 Relative mRNA levels of the globin and erythrocyte membrane protein genes in the analysed patient
a-Globin b-Globin ANK1 SLC4A1 SPTA1 SPTB EPB42
Proband 0.27 (0.001) 2.09 (0.002) 2.08 (0.001) 2.45 (0.003) 2.18 (0.007) 0.79 (0.326) 0.55 (0.032)
P-values are given in brackets.
ANK1, ankyrin, erythrocytic; SLC4A1, solute carrier family 4, anion exchanger, member 1, band 3; SPTA1, spectrin, alpha, erythrocytic 1; SPTB,
spectrin, beta, erythrocytic; EPB42, protein 4.2, erythrocytic.
Maciag et al. Protein 4.2 gene mutations and thalassaemia alpha
ª 2009 The Authors
Journal compilation ª 2009 John Wiley & Sons A ⁄ S 375tary spherocytosis. However, a-thalassaemia and HS are
rarely inherited together. Few reports (15, 16) are known
to describe combinations of hereditary spherocytosis and
a-thalassaemia. Heaton et al. 1991 (15) conclude that
patients with both diseases had milder presence of sphero-
cytosis. Li et al. 1994 (16) state that the haemolytic effect
of hereditary spherocytosis is modulated by the increased
osmotic resistance of red blood cells in patients with both
disorders. Similar results were shown by del Giudice et al.,
1993 (17) who demonstrated that b-thalassaemia traits
‘silence’ most of the clinical ﬁndings associated with HS.
In our patient, the coexistence of the erythrocyte mem-
brane protein 4.2 gene mutations and a-thalassaemia
causing deletions results in a decrease in haemoglobin
concentration, microcytosis, and also an increasing red
cell distribution width (RDW) value.
A possible direct interaction between the globin chain
and membrane proteins could have had an effect on the
sensitivity of the EMA test. Due to a lack of clear con-
clusions from the SDS-PAGE and EMA tests, mRNA
relative quantiﬁcation of the globin and red blood cell
membrane protein genes was introduced for further
investigation of the cause of anaemia in the proband.
The decreased level of the a-globin transcript in the
analysed patient prompted us to perform DNA analysis
of the alpha globin gene. Thus, the 3.7 kb deletion
within the a-globin gene cluster ()a
3.7⁄)a
3.7) was
detected in the proband.
In addition, mRNA relative quantiﬁcation of the red
cell membrane protein genes in the Polish patient indi-
cated the EPB42 gene as the one that could also be
involved in anaemia pathogenesis. Sequencing analysis
revealed the presence of two novel mutations in the pro-
tein 4.2 gene: a G1701A genetic change that predicts an
alanine to threonine at position 567 of the protein
(A567T) and a T ﬁ A substitution that is located at
position +6 of the donor splice site of intron 2
(IVS2nt+6T>A). Because of the location near the 5¢
splice site of the intron 2, the T ﬁ A substitution in the
sixth nucleotide of intron 2 of the EPB42 gene could
reduce activity of this splice site and lead to mRNA
instability. It has already been shown that mutations at
position +6 of the b-globin gene intron affect its splic-
ing (18) and this result was recently conﬁrmed by our
own work, in which we show marked reduction in the
relative amount of b-globin transcript in patients carry-
ing genetic changes at position +6 of the b-globin gene
intron (19). However, the T ﬁ A substitution in the
sixth nucleotide of intron 2 of the EPB42 gene detected
in Polish patient does not totally destabilise mRNA car-
rying this genetic change. This was conﬁrmed by
sequencing cDNA product across the A567T substitution
that revealed heterozygotic form of the A567T mutation
(data not shown). The nucleotide substitution
IVS2nt+6T>A is the second splicing affecting mutation
reported in the EPB42 gene so far. The previous one,
called protein 4.2 Notame, was found in a Japanese man
and involved a single nucleotide substitution G ﬁ Ai n
the ﬁrst nucleotide of intron 6 (20). The vast majority of
genetic changes identiﬁed in the EPB42 gene are mis-
sense mutations (21) and most of them were found in
Japan. The only ﬁve protein 4.2 variants identiﬁed out-
side the Japanese population are: protein 4.2 Tozeur
(R310Q) (6), protein 4.2 Lisboa (136⁄137 delG) (7), pro-
tein 4.2 Nippon (T142A) (8), protein 4.2 Nancy (949
delG) (9) and protein 4.2 Hammersmith (1747G>T)
(10). Our patient, who was found to be a compound het-
erozygote for two novel mutations in the EPB42 gene,
represents the fourth case of the EPB42 gene mutations
discovered in the European population.
In conclusion, our data suggest that measurement of
mRNA levels of globin and erythrocyte membrane pro-




Figure 2 (A) Pattern of RsaI digestion of the PCR product containing
exon 10 (detection of G1701A substitution in the EPB42 gene with
genomic DNA as a template): M, 100 bp marker; P, proband; wt,
wild-type. (B) Sequence analysis of the fragment around the donor
splice site of intron 2 of the EPB42 gene (the three last nucleotides of
the EPB42 exon 2 were put in rectangle; genomic DNA was used as
a template).
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screening of patients with not clariﬁed hereditary hae-
moytic anaemia, especially for cases with down-regulated
gene expression or mRNA instability.
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